Back to search
FDAFDA · Food and drugs·Recall number D-0499-2023

Ropinirole 2mg tablets, packaged in 180-count bottles, Rx only, Repackaged by: RemedyRepack Inc., Indiana, PA 15701, NDC70518-2750-00

Published April 12, 2023 · Recall initiated: March 20, 2023

Summary

FDA records drug Class II recall D-0499-2023, published April 12, 2023 and initiated March 20, 2023. Recalling firm: RemedyRepack Inc.; Status: Terminated; Reported quantity: 3 bottles; Lot: Lot#: B1630017-040122, Exp. Date 04/30/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

cGMP Deviations

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
RemedyRepack Inc.
Distributor
RemedyRepack distributed product to consignees nationwide within the United States
Lot
Lot#: B1630017-040122, Exp. Date 04/30/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Ropinirole 2mg tablets, packaged in 180-count bottles, Rx only, Repackaged by: RemedyRepack Inc., Indiana, PA 15701, NDC70518-2750-00 recalled?

Yes. FDA published recall D-0499-2023 on April 12, 2023. Reported hazard: cGMP Deviations

What should I do if I have this product?

Voluntary: Firm initiated · Letter